Abstracts tagged "SLE and cognitive dysfunction"

Abstract Number: 1572 • 2019 ACR/ARP Annual Meeting
Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors
Dorcas Beaton ¹, Robin Green ², Lesley Ruttan ², Joan Wither ³, Oshrat Tayer-shifman⁴, Maria Tartaglia ⁵, Mahta Kakvan ⁴, Nicole Anderson ⁴, Jiandong Su ⁴, Moe Zandy ⁴, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁴, ¹St. Michael's Hospital, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE) and its course may change over time. The objective was to determine…
Abstract Number: 2809 • 2017 ACR/ARHP Annual Meeting
Spatial Navigation Impairment Associated with Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus
Erik Anderson¹, Elisabeth J. Ploran², Betty Diamond³, Bruce Volpe⁴, Cynthia Aranow⁵ and Meggan Mackay^6,7, ¹Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²Department of Psychology, Hofstra University, Hempstead, NY, ³Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhassett, NY
Background/Purpose: Cognitive impairment is well-documented in SLE with considerable impact on quality of life but attribution is limited by a lack of biomarkers that distinguish…
Abstract Number: 2956 • 2015 ACR/ARHP Annual Meeting
Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus
Stephanie Nantes¹, Murray Urowitz², Dafna Gladman², Ashneet Dhaliwal¹ and Zahi Touma², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: It is unclear whether cognitive complaints in patients with SLE are indicative of true Cognitive Impairment (CI) or underlying depression or anxiety. To determine:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].